Enlivex (NASDAQ: ENLV) lists RAIN treasury token on WhiteBIT exchange
Rhea-AI Filing Summary
Enlivex Therapeutics reported that its primary digital treasury asset, the RAIN token, has been listed on the WhiteBIT cryptocurrency exchange effective January 21, 2026. WhiteBIT is described as the largest European cryptocurrency exchange by traffic and part of W Group, serving more than 35 million customers globally.
The company expects RAIN trading on WhiteBIT to expand market access and enhance secondary market liquidity for the token, supporting its digital asset treasury strategy centered on RAIN. Enlivex remains a clinical-stage macrophage reprogramming immunotherapy company focused on late-stage development of Allocetra for osteoarthritis, while also positioning RAIN as its primary treasury reserve asset to give investors exposure to this digital token.
Positive
- None.
Negative
- None.
Insights
Enlivex adds major exchange listing for its RAIN treasury token while maintaining core osteoarthritis drug focus.
Enlivex describes RAIN as its primary digital treasury asset and reports that the token is now listed on the WhiteBIT cryptocurrency exchange, effective January 21, 2026. WhiteBIT is characterized as the largest European exchange by traffic and part of W Group, which Enlivex says serves more than 35 million customers, suggesting broader potential access and trading venues for RAIN.
The company states that the commencement of RAIN trading on WhiteBIT is expected to broaden regional market access and enhance secondary market liquidity for the token. This aligns with its previously announced treasury strategy focused on acquiring RAIN and using it as a governance and utility token tied to a decentralized predictions and options protocol on the Arbitrum network.
Enlivex also reiterates its core business as a clinical-stage macrophage reprogramming immunotherapy company developing Allocetra for osteoarthritis, emphasizing the large unmet need and lack of approved disease-modifying therapies. The filing highlights significant risks and uncertainties around both clinical development and its digital asset strategy, including volatility in RAIN’s price and liquidity and evolving regulatory treatment of crypto assets.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What did Enlivex Therapeutics (ENLV) announce about the RAIN token?
What is the significance of WhiteBIT for Enlivex’s RAIN token?
How does the RAIN token fit into Enlivex Therapeutics’ strategy?
What is the RAIN token and what protocol does it support?
What is Enlivex Therapeutics’ main clinical focus besides digital assets?
What risks does Enlivex highlight regarding its digital asset treasury strategy?
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
under the Securities Exchange Act of 1934
For the month of: January 2026
Commission file number: 001-36578
ENLIVEX THERAPEUTICS LTD.
(Translation of registrant’s name into English)
14 Einstein Street, Nes Ziona, Israel 7403618
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
On January 26, 2026, Enlivex Therapeutics Ltd., a company organized under the laws of the State of Israel, issued a press release announcing that, effective January 21, 2026, its treasury asset, the RAIN token, has been listed on the WhiteBIT cryptocurrency exchange. A copy of such press release is furnished as Exhibit 99.1 to this Report on Form 6-K and incorporated herein by reference.
| Exhibit No. | ||
| 99.1 | Press Release Issued by Enlivex Therapeutics Ltd. on January 26, 2026 |
1
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Enlivex Therapeutics Ltd. | ||
| (Registrant) | ||
| By: | /s/ Oren Hershkovitz | |
|
Name: Title: |
Oren Hershkovitz Chief Executive Officer | |
Date: January 26, 2026
2
Exhibit 99.1
Enlivex Treasury Portfolio Update: Listing of the RAIN Token on WhiteBIT, a Leading Cryptocurrency Exchange
Listing expected to expand market access and secondary liquidity for Enlivex’s primary digital treasury asset
Nes-Ziona, Israel, Jan. 26, 2026 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, “Enlivex” or “the Company”) today reported that its primary treasury asset, the RAIN token, has been listed on the WhiteBIT cryptocurrency exchange effective January 21, 2026, expanding access to the token across a major global digital asset trading platform.
WhiteBIT is the largest European cryptocurrency exchange by traffic. Founded in 2018, the platform is part of W Group, which serves more than 35 million customers globally. The commencement of RAIN trading on WhiteBIT is expected to broaden regional market access and enhance secondary market liquidity for RAIN, supporting the continued development of market infrastructure and accessibility for Enlivex’s digital asset treasury strategy.
Enlivex previously announced the launch of its digital asset treasury strategy focused on the acquisition of RAIN tokens. RAIN serves as the governance and utility token of a fully decentralized predictions and options protocol built on the Arbitrum network. The protocol enables users globally to create, trade, and resolve markets tied to real-world events through a transparent and automated on-chain framework.
ABOUT ENLIVEX
Enlivex is a clinical stage macrophage reprogramming immunotherapy company currently focused on the late-stage clinical development of Allocetra™, a novel therapy designed to treat the joint disease osteoarthritis. Additionally, Enlivex is the first publicly-listed company to have developed a treasury strategy centered on RAIN, which currently serves as the primary treasury reserve asset of the Company. In adopting its treasury policy, Enlivex intends to provide investors with exposure to RAIN and to advocate for its role as digital capital.
With respect the Company’s clinical development focus, osteoarthritis is by far the most common form of arthritis, affecting more than 32.5 million Americans and more than 300 million individuals worldwide. About half of knees with ACL injuries develop osteoarthritis within 5 to 15 years. 78 million Americans are projected to have osteoarthritis by the year 2040. Symptomatic knee osteoarthritis is particularly prevalent and disabling, with 40% of men and 47% of women developing knee osteoarthritis in their lifetimes. Osteoarthritis accounts for over one million hospitalizations annually in the United States, primarily for total joint replacement. The burden of osteoarthritis is enormous, and the need for treatments that reduce pain and attendant disability for persons with osteoarthritis is critical. To the Company’s knowledge, there are currently no medications approved by either the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA) that have been demonstrated to arrest, slow or reverse progression of structural damage in the joint.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements may be identified by words such as “expects,” “plans,” “projects,” “will,” “may,” “anticipates,” “believes,” “should,” “would,” “could,” “intends,” “estimates,” “suggests,” “target,” “has the potential to,” “goal,” and other words of similar meaning, including statements relating to the anticipated benefits of the Company’s digital asset treasury strategy; the assets to be held by the Company; the expected future market, price, trading activity, and liquidity of the RAIN token; the impact of expanded exchange listings and increased token liquidity on market participation and accessibility; the potential effects of digital asset liquidity on the liquidity of the Company’s ordinary shares; macroeconomic, political, and regulatory conditions surrounding digital assets; the Company’s plans for value creation and strategic positioning; market size and growth opportunities; regulatory conditions; competitive position; technological and market trends; future financial condition and performance; expected clinical trial results; market opportunities for the results of current clinical studies and preclinical experiments; and the effectiveness of, and market opportunities for, ALLOCETRA™ programs.
Each forward-looking statement contained in this press release is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statement. Applicable risks and uncertainties include, among others, the risk of failure to realize the anticipated benefits of the Company’s digital asset treasury strategy; changes in business, market, financial, political, and regulatory conditions; risks relating to the Company’s operations and business, including the highly volatile nature of the price, trading volume, and liquidity of RAIN and other cryptocurrencies; risks associated with digital asset exchange listings, trading venues, and market infrastructure; the risk that the price and liquidity of the Company’s ordinary shares may be correlated with the price or liquidity of the digital assets it holds; risks related to increased competition in the industries in which the Company operates; risks relating to significant legal, commercial, regulatory, and technical uncertainty regarding digital assets generally; risks relating to the treatment of crypto assets for U.S. and foreign tax purposes; and those risks and uncertainties identified in the Company’s filings with the Securities and Exchange Commission. The forward-looking statements in this press release speak only as of the date of this document, and the Company undertakes no obligation to update or revise any of these statements, except as required by applicable law.no obligation to update or revise any of these statements, except as required by applicable law.
ENLIVEX CONTACT
Shachar Shlosberger, CFO
Enlivex Therapeutics, Ltd.
shachar@enlivex.com
INVESTOR RELATIONS CONTACT
KCSA Strategic Communications
Jack Perkins
Enlivex@KCSA.com